NASDAQ
29.45USD
+0.22 (+0.75%)
We have scored 7 news catalysts on Schrödinger, Inc. (SDGR) over the past 12 months. The biggest single-day move next to one of them came Dec 20, 2025, when SDGR closed +2.7%: “Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought”. Coverage across the window leans positive (average ticker sentiment +0.29). Most of the impact sits in sector healthcare and revenue growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.2B
P/E
—
EPS
—
Beta
1.69
52W range
10.945-31.595
Day range
28.40–30.24
Open
28.98
Prev close
29.23
Volume
2M
Avg volume
1.4M
Dividend
0.00
IPO
2020-02-05
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Schrödinger, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SDGR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
